+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Global tissue diagnostics market is expected to reach $8.24 Bn by 2029”, says Visiongain

08 January 2020
Pharma

Visiongain’s new report the Tissue Diagnostics Market Report : Forecasts by Product (Consumables, Instruments), by Product (Immunohistochemistry, in Situ Hybridization, Digital Pathology, Others), by Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer, Others), by End User (Hospitals, Research Labs, Pharmaceutical Companies, Research Organizations), plus analysis of leading companies operating in the global tissue diagnostics market.

In 2019, the global tissue diagnostics market was valued at $4.09 billion and is expected to reach $8.24 billion by 2029 at a CAGR of 7.2% over the forecast period. Rising cancer prevalence all over the world, expanding healthcare infrastructure in developing countries, growing healthcare diagnostics affordability, technological advancement in imaging, and growth in personalized therapeutics is expected to increase tissue diagnostics market expansion over the projected period.

Improving healthcare infrastructure in developing countries such as India, China, Indonesia, Singapore, Malaysia, South Korea, Brazil, and Colombia is expected to encourage healthcare service providers to expand their facilities in these countries. Additionally, increasing disposable income followed by increasing healthcare spending has increased market penetration of tissue diagnostics over the past few years and the trend is expected to continue over the course of time.

Technological advancement in tissue diagnostics is expected to open avenues in the global healthcare industry. For instance, in 2018, According to University of Illinois, a new microscope system can image living tissue in real time and in molecular detail, without any chemicals or dyes. Some other prominent technologies innovated in 2017 are a Mass Spec Pen To Rapidly Identify Cancer, Paper Point-of-Care Zika Test, Transparent Tissues for Pathological Diagnosis, Paper-based Electrochemical Diagnostics, Microfluidic Chip to Predict Preterm Birth, Smartphone TRI Analyzer, and Wearable Sweat Sensor.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

Read

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

Read

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

Read

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2022-2032

The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.

13 September 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever